|
|
发表于 2009-5-18 03:12 PM
|
显示全部楼层
那估计炒垃圾股，还是有可能的，垃圾股就是锻炼人的心肺功能的~
我手头就有两个垃圾股，都是最近进的
heb我进的0,85美元，现在翻番了，1,9美元了~但是量不多
但是我还有genta，补了一次 ，成本在0,01欧左右，现在 ...
gilbert 发表于 2009-5-18 14:40 
关于genta的独立分析，赌一把，对了就发了，输了就认栽吧。
On 5/12/09, Genta reported its quarterly operating results and provided an update on its lead experimental cancer drug Genasense (oblimersen sodium). AGENDA is a Phase 3, randomized, double-blind trial in 315 patients with advanced melanoma which is designed to confirm certain safety and efficacy results from a previous randomized trial of Genasense combined with dacarbazine in patients who have not previously received chemotherapy. AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH, a tumor-derived enzyme that is readily detected in blood.
Key upcoming milestones for Genasense in the Phase 3 AGENDA trial include (1) a final safety and futility analysis by the independent Data Monitoring Committee is expected in May 2009 and (2) Progression-free survival (PFS) results are expected Q4 2009 if the trial proceeds to completion pending the safety and futility analysis in May. Genta included the following disclaimer regarding its funding and liquidity – Absent additional funding, the Company currently projects that it will run out of funds in June 2009. The terms of the 2009 Notes enable those note-holders, at their option, to purchase additional notes with similar terms. The Company does not have any additional financing in place. |
|
狗仔卡
